FSSP published economic evaluations from Japan

Reviwing CEA from Japan

​

Poll

For 1.5 years of complication they paid and extra 1893 US- what do you think? Let us discuss this the value to pay for one year free of complication is

• high for Jordan

• affordable for Jordan

• Need a value for acceptance or rejection

Poll

What do you think of Population difference (Japan vs Jordan)

• BMI vary between both countries

• dietry risk for glucose control

• age and duration of DM might differ too

• all of the above

Poll

costs in Jordan vs Japan

• Japan and Jordan run a universal health system-cost are valued in the same way

• the cost of complications is beared diffrently in both countries- Jordan is fragmented and Prices subsided highly

Poll

• what about Risk of complications

• Risk vary between both countries

• Risk are similar across countries- effectivness measures applicable to Jordan

Poll

Over all conclusion, would you recommend change in practice in Jordan

• I need local data on both costs and outcome from Jordan

• I agree with the study value for 1 year and thus I recomend the treatment change

Poll

The reduction of total costs in MIT over CIT was mainly due to reduced costs for management of diabetic complications- what is your though on use of Japan result to guide local decision in Iraq?

• cost of treatment and complications in Jordan are lower then Japan potentially the MIT is cost-effective in Iraq

• without ensuring effectiveness measures on local data, cost effectiveness can’t be decided.

• Jordanians have a high risk for CVD and diabetes potentially the effectiveness measure are more significant in Jordan. Thus cost effectiveness result from Japan can be applied in Jordan